MDGL

MadrigalF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$7.25

-98.5% vs current

Most likely

Base case

60%

Probability

Target price

$2.90

-99.4% vs current

B-

Bear case

20%

Probability

Target price

$0.73

-99.8% vs current

AI sentiment snapshot

Latest data as of 2026-01-16

AI commentary

Third‑party price‑target aggregates show nominal targets far above the authoritative anchor, creating a clear valuation disconnect [#SERP-1] [#SERP-3]. Near‑term sentiment is cautious and headline‑driven around clinical and corporate‑update windows, while successful binary outcomes would produce outsized upside. This mix of high execution risk and event-driven upside underpins the current buy view with moderate confidence.

RankAlpha Sentiment AI - 2026-01-16

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-02-28eventQuarterly earnings / corporate updateHigh impact

Company quarterly report and corporate update (date estimated as quarter end; assumption noted), which can reset guidance and near-term sentiment.

2026-04-16catalystPotential late‑stage NASH readout / regulatory updateHigh impact

Estimated late‑stage clinical readout or regulatory update for resmetirom; date conservatively estimated when no firm date disclosed [#SERP-1].

2027-01-16catalystCommercial uptake / label expansion outcomesHigh impact

Outcome-driven revenue inflection from broader label/commercial adoption over the next year; modeled as long-term upside driver.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-16 • Updated nightlySource: Internal modelMethodology